Discovery of (2R)-N-[3-[2-[(3-Methoxy-1-methyl-pyrazol-4-yl)amino]pyrimidin-4-yl]-1H-indol-7-yl]-2-(4-methylpiperazin-1-yl)propenamide (AZD4205) as a Potent and Selective Janus Kinase 1 Inhibitor

被引：44

作者：

Su, Qibin ^{[1
]}

Banks, Erica ^{[1
]}

Bebernitz, Geraldine ^{[1
]}

Bell, Kirsten ^{[1
]}

Borenstein, Cassandra F. ^{[1
]}

Chen, Huawei ^{[1
]}

Chuaqui, Claudio E. ^{[1
]}

Deng, Nanhua ^{[1
]}

Ferguson, Andrew D. ^{[2
,3
]}

Kawatkar, Sameer ^{[1
]}

Grimster, Neil P. ^{[1
]}

Ruston, Linette ^{[1
]}

Lyne, Paul D. ^{[1
]}

Read, Jon A. ^{[3
]}

Peng, Xianyou ^{[4
]}

Pei, Xiaohui ^{[4
]}

Fawell, Stephen ^{[1
]}

Tang, Zhanlei ^{[4
]}

Throner, Scott ^{[1
]}

Vasbinder, Melissa M. ^{[1
]}

Wang, Haoyu ^{[4
]}

Winter-Holt, Jon ^{[5
]}

Woessner, Richard ^{[1
]}

Wu, Allan ^{[2
]}

Yang, Wenzhan ^{[6
]}

Zinda, Michael ^{[1
]}

Kettle, Jason G. ^{[5
]}

机构：

[1] AstraZeneca R&D, Oncol R&D, Waltham, MA 02451 USA

[2] AstraZeneca R&D, R&D, Discovery Sci, Waltham, MA 02451 USA

[3] AstraZeneca R&D, R&D, Discovery Sci, Cambridge CB4 0WG, England

[4] Pharmaron Beijing Co Ltd, Beijing 100176, Peoples R China

[5] AstraZeneca R&D, Oncol R&D, Cambridge CB4 0WG, England

[6] R&D, Pharmaceut Sci, Early Product Dev, Boston, MA 02451 USA

来源：

JOURNAL OF MEDICINAL CHEMISTRY | 2020年 / 63卷 / 09期

关键词：

PATENT LITERATURE 2013-2015; JAK-FAMILY KINASES; RHEUMATOID-ARTHRITIS; INADEQUATE RESPONSE; STAT3; ACTIVATION; PATHWAY; CANCER; IDENTIFICATION; PROLIFERATION; PEFICITINIB;

D O I：

10.1021/acs.jmedchem.9b01392

中图分类号：

R914 [药物化学];

学科分类号：

100701 ;

摘要：

JAK1, JAK2, JAK3, and TYK2 belong to the JAK (Janus kinase) family. They play critical roles in cytokine signaling. Constitutive activation of JAK/STAT pathways is associated with a wide variety of diseases. Particularly, pSTAT3 is observed in response to the treatment with inhibitors of oncogenic signaling pathways such as EGFR, MAPK, and AKT and is associated with resistance or poorer response to agents targeting these pathways. Among the JAK family kinases, JAK1 has been shown to be the primary driver of STAT3 phosphorylation and signaling; therefore, selective JAK1 inhibition can be a viable means to overcome such treatment resistances. Herein, an account of the medicinal chemistry optimization from the promiscuous kinase screening hit 3 to the candidate drug 21 (AZD4205), a highly selective JAK1 kinase inhibitor, is reported. Compound 21 has good preclinical pharmacokinetics. Compound 21 displayed an enhanced antitumor activity in combination with an approved EGFR inhibitor, osimertinib, in a preclinical non-small-cell lung cancer (NSCLC) xenograft NCI-H1975 model.

引用

页码：4517 / 4527

页数：11

共 43 条

[1]

Aastrand A.B.M.GrimsterN.P., 2017, Patent No. [WO201750938, 201750938]

[2] Activation of STAT3 in thymic epithelial tumours correlates with tumour type and clinical behaviour [J].

Chang, K. -C. ;

Wu, M. -H. ;

Jones, D. ;

Chen, F. -F. ;

Tseng, Y. -L. .

JOURNAL OF PATHOLOGY, 2006, 210 (02) :224-233

[3] Persistent STAT3 activation in colon cancer is associated with enhanced cell proliferation and tumor growth [J].

Corvinus, FM ;

Orth, C ;

Moriggl, R ;

Tsareva, SA ;

Wagner, S ;

Pfitzner, EB ;

Baus, D ;

Kaufmann, R ;

Huber, LA ;

Zatloukal, K ;

Beug, H ;

Öhlschäger, P ;

Schütz, A ;

Halbhuber, KJ ;

Friedrich, K .

NEOPLASIA, 2005, 7 (06) :545-555

[4] Discovery of a Potent and Selective EGFR Inhibitor (AZD9291) of Both Sensitizing and T790M Resistance Mutations That Spares the Wild Type Form of the Receptor [J].

Finlay, M. Raymond V. ;

Anderton, Mark ;

Ashton, Susan ;

Ballard, Peter ;

Bethel, Paul A. ;

Box, Matthew R. ;

Bradbury, Robert H. ;

Brown, Simon J. ;

Butterworth, Sam ;

Campbell, Andrew ;

Chorley, Christopher ;

Colclough, Nicola ;

Cross, Darren A. E. ;

Currie, Gordon S. ;

Grist, Matthew ;

Hassall, Lorraine ;

Hill, George B. ;

James, Daniel ;

James, Michael ;

Kemmitt, Paul ;

Klinowska, Teresa ;

Lamont, Gillian ;

Lamont, Scott G. ;

Martin, Nathaniel ;

McFarland, Heather L. ;

Mellor, Martine J. ;

Orme, Jonathon P. ;

Perkins, David ;

Perkins, Paula ;

Richmond, Graham ;

Smith, Peter ;

Ward, Richard A. ;

Waring, Michael J. ;

Whittaker, David ;

Wells, Stuart ;

Wrigley, Gail L. .

JOURNAL OF MEDICINAL CHEMISTRY, 2014, 57 (20) :8249-8267

[5] Discovery of CP-690,550: A Potent and Selective Janus Kinase (JAK) Inhibitor for the Treatment of Autoimmune Diseases and Organ Transplant Rejection [J].

Flanagan, Mark E. ;

Blumenkopf, Todd A. ;

Brissette, William H. ;

Brown, Matthew F. ;

Casavant, Jeffrey M. ;

Shang-Poa, Chang ;

Doty, Jonathan L. ;

Elliott, Eileen A. ;

Fisher, Michael B. ;

Hines, Michael ;

Kent, Craig ;

Kudlacz, Elizabeth M. ;

Lillie, Brett M. ;

Magnuson, Kelly S. ;

McCurdy, Sandra P. ;

Munchhof, Michael J. ;

Perry, Bret D. ;

Sawyer, Perry S. ;

Strelevitz, Timothy J. ;

Subramanyam, Chakrapani ;

Sun, Jianmin ;

Whipple, David A. ;

Changelian, Paul S. .

JOURNAL OF MEDICINAL CHEMISTRY, 2010, 53 (24) :8468-8484

[6] Mutations in the EGFR kinase domain mediate STAT3 activation via IL-6 production in human lung adenocarcinomas [J].

Gao, Sizhi Paul ;

Mark, Kevin G. ;

Leslie, Kenneth ;

Pao, William ;

Motoi, Noriko ;

Gerald, William L. ;

Travis, William D. ;

Bornmann, William ;

Veach, Darren ;

Clarkson, Bayard ;

Bromberg, Jacqueline F. .

JOURNAL OF CLINICAL INVESTIGATION, 2007, 117 (12) :3846-3856

[7] Peficitinib, a JAK Inhibitor, in Combination With Limited Conventional Synthetic Disease-Modifying Antirheumatic Drugs in the Treatment of Moderate-to-Severe Rheumatoid Arthritis [J].

Genovese, Mark C. ;

Greenwald, Maria ;

Codding, Christine ;

Zubrzycka-Sienkiewicz, Anna ;

Kivitz, Alan J. ;

Wang, Annie ;

Shay, Kathyjo ;

Wang, Xuegong ;

Garg, Jay P. ;

Cardiel, Mario H. .

ARTHRITIS & RHEUMATOLOGY, 2017, 69 (05) :932-942

[8] Efficacy and Safety of ABT-494, a Selective JAK-1 Inhibitor, in a Phase IIb Study in Patients With Rheumatoid Arthritis and an Inadequate Response to Methotrexate [J].

Genovese, Mark C. ;

Smolen, Josef S. ;

Weinblatt, Michael E. ;

Burmester, Gerd R. ;

Meerwein, Sebastian ;

Camp, Heidi S. ;

Wang, Li ;

Othman, Ahmed A. ;

Khan, Nasser ;

Pangan, Aileen L. ;

Jungerwirth, Steven .

ARTHRITIS & RHEUMATOLOGY, 2016, 68 (12) :2857-2866

[9] Baricitinib in Patients with Refractory Rheumatoid Arthritis [J].

Genovese, Mark C. ;

Kremer, Joel ;

Zamani, Omid ;

Ludivico, Charles ;

Krogulec, Marek ;

Xie, Li ;

Beattie, Scott D. ;

Koch, Alisa E. ;

Cardillo, Tracy E. ;

Rooney, Terence P. ;

Macias, William L. ;

de Bono, Stephanie ;

Schlichting, Douglas E. ;

Smolen, Josef S. .

NEW ENGLAND JOURNAL OF MEDICINE, 2016, 374 (13) :1243-1252

[10] Discovery and Optimization of a Novel Series of Highly Selective JAK1 Kinase Inhibitors [J].

Grimster, Neil P. ;

Anderson, Erica ;

Alimzhanov, Marat ;

Bebernitz, Geraldine ;

Bell, Kirsten ;

Chuaqui, Claudio ;

Deegan, Tracy ;

Ferguson, Andrew D. ;

Gero, Thomas ;

Harsch, Andreas ;

Huszar, Dennis ;

Kawatkar, Aarti ;

Kettle, Jason G. ;

Lyne, Paul ;

Read, Jon A. ;

Costa, Caroline Rivard ;

Ruston, Linette ;

Schroeder, Patricia ;

Shi, Jie ;

Su, Qibin ;

Throner, Scott ;

Toader, Dorin ;

Vasbinder, Melissa ;

Woessner, Richard ;

Wang, Haixia ;

Wu, Allan ;

Ye, Minwei ;

Zheng, Weijia ;

Zinda, Michael .

JOURNAL OF MEDICINAL CHEMISTRY, 2018, 61 (12) :5235-5244

← 1 2 3 4 5 →